UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2013-06, Vol.381 (9884), p.2167-2175

2013

Volltextzugriff (PDF)

Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study

Journal of neurology, 2020-10, Vol.267 (10), p.2851-2864

2020

Volltextzugriff (PDF)

Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination

Therapeutic advances in neurological disorders, 2021, Vol.14, p.1756286420987941-1756286420987941

2021

Volltextzugriff (PDF)

Immune Response to Seasonal Influenza Vaccine in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Long-term Daclizumab Beta: A Prospective, Open-Label, Single-Arm Study

International journal of MS care, 2017-05, Vol.19 (3), p.141-147

2017

Volltextzugriff (PDF)

Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma

Neuro-oncology advances, 2023-01, Vol.5 (1), p.vdac183-vdac183

2023

Volltextzugriff (PDF)

The CD25-binding antibody Daclizumab High-Yield Process has a distinct glycosylation pattern and reduced antibody-dependent cell-mediated cytotoxicity in comparison to Zenapax

mAbs, 2016-10, Vol.8 (7), p.1417-1424

2016

Volltextzugriff (PDF)

Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis

Expert review of clinical pharmacology, 2014-01, Vol.7 (1), p.9-19

2014

Volltextzugriff (PDF)

Human Beings with Rights: Unions and Democracy in the 21st Century

The innovation journal, 2014-01, Vol.19 (1), p.1-9

Robinson, Randy

2014

Volltextzugriff (PDF)

First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.3001-3001

2024

Volltextzugriff (PDF)

First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors

Clinical cancer research, 2021-07, Vol.27 (13), p.3556-3566

2021

Volltextzugriff (PDF)

Matching-Adjusted Comparison of Daclizumab Beta vs Fingolimod for the Treatment of Relapsing-Remitting Multiple Sclerosis (P1.356)

Neurology, 2018-04, Vol.90 (15_supplement)

2018

Volltextzugriff (PDF)

Escherichia coli Secretion of an Active Chimeric Antibody Fragment

Science (American Association for the Advancement of Science), 1988-05, Vol.240 (4855), p.1041-1043

1988

Volltextzugriff (PDF)

Safety and Efficacy of Long-Term Treatment With Daclizumab Beta: 6-Year Results From the SELECTED Extension Study (P6.390)

Neurology, 2018-04, Vol.90 (15_supplement)

2018

Volltextzugriff (PDF)

First-in-human phase 1 study of ABBV-085, an antibody-drug conjugate (ADC) targeting LRRC15, in sarcomas and other advanced solid tumors

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.3004-3004

2019

Volltextzugriff (PDF)

Abstract 953: LRRC15 is a novel antigen in sarcoma and the therapeutic target of the antibody-drug conjugate (ADC) ABBV-085

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.953-953

2018

Volltextzugriff (PDF)

Modeling of CZT Response to Gamma Photons Using MCNP and Garfield

MRS proceedings, 2015, Vol.1792 (1), Article mrss15-2137042

2015

Volltextzugriff (PDF)

Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2

Cancer research (Chicago, Ill.), 1990-09, Vol.50 (17), p.5234-5239

1990

Volltextzugriff (PDF)

Long-Term Efficacy of Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis: 3 Year Results from the SELECTED Extension Study (P7.226)

Neurology, 2015-04, Vol.84 (14_supplement)

2015

Volltextzugriff (PDF)

Immune Response to Seasonal Influenza Vaccine in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Long-term Daclizumab Beta

International journal of MS care, 2017-05, Vol.19 (3), p.141-147

2017

Volltextzugriff (PDF)

Abbott ARCHITECT i Phenytoin Assay Versus Similar Assays for Measuring Free Phenytoin Concentrations

Laboratory medicine, 2014-05, Vol.45 (2), p.176-181

2014

Volltextzugriff (PDF)

High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis

Journal of autoimmunity, 2008-09, Vol.31 (2), p.91-97

2008

Volltextzugriff (PDF)

On One-Sided Stochastic Games and Their Applications to Finance

Stochastic models, 2012-01, Vol.28 (1), p.1-14

2012

Volltextzugriff (PDF)

Abbott ARCHITECT iPhenytoin assay versus similar assays for measuring free phenytoin concentrations

Laboratory medicine, 2014-03, Vol.45 (2), p.176-181

2014

Volltextzugriff (PDF)

FLUCTUATIONS OF A NONMONOTONE MARKED POINT PROCESS UNDER A TIME CONSTRAINT

Neural, parallel & scientific computations, 2012-12, Vol.20 (3-4), p.249-262

2012

Volltextzugriff (PDF)

1 – 25 von 210

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(162)
Mit Volltextzugriff
(158)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(209)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(120)
Life Sciences & Biomedicine
(99)
Humans
(69)
Female
(33)
Male
(31)
Biological And Medical Sciences
(25)
Adult
(23)
Middle Aged
(22)
Animals
(20)
Neurosciences & Neurology
(17)
Aged
(15)
Fundamental And Applied Biological Sciences. Psychology
(13)
Medical Sciences
(13)
Multidisciplinary Sciences
(12)
Neurosciences
(12)
Science & Technology - Other Topics
(12)
Physical Sciences
(11)
Patients
(10)
Young Adult
(10)
Covid-19
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study

Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination

Immune Response to Seasonal Influenza Vaccine in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Long-term Daclizumab Beta: A Prospective, Open-Label, Single-Arm Study

Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma

The CD25-binding antibody Daclizumab High-Yield Process has a distinct glycosylation pattern and reduced antibody-dependent cell-mediated cytotoxicity in comparison to Zenapax

Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis

Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration

Human Beings with Rights: Unions and Democracy in the 21st Century

First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors

First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors

Matching-Adjusted Comparison of Daclizumab Beta vs Fingolimod for the Treatment of Relapsing-Remitting Multiple Sclerosis (P1.356)

Escherichia coli Secretion of an Active Chimeric Antibody Fragment

Safety and Efficacy of Long-Term Treatment With Daclizumab Beta: 6-Year Results From the SELECTED Extension Study (P6.390)

First-in-human phase 1 study of ABBV-085, an antibody-drug conjugate (ADC) targeting LRRC15, in sarcomas and other advanced solid tumors

Abstract 953: LRRC15 is a novel antigen in sarcoma and the therapeutic target of the antibody-drug conjugate (ADC) ABBV-085

Modeling of CZT Response to Gamma Photons Using MCNP and Garfield

Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2

Long-Term Efficacy of Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis: 3 Year Results from the SELECTED Extension Study (P7.226)

Immune Response to Seasonal Influenza Vaccine in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Long-term Daclizumab Beta

Abbott ARCHITECT i Phenytoin Assay Versus Similar Assays for Measuring Free Phenytoin Concentrations

High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis

On One-Sided Stochastic Games and Their Applications to Finance

Abbott ARCHITECT iPhenytoin assay versus similar assays for measuring free phenytoin concentrations

FLUCTUATIONS OF A NONMONOTONE MARKED POINT PROCESS UNDER A TIME CONSTRAINT

Suchergebnisse filtern